ArticleCritical care (London, England)2015
Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy.
Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Complications of a lung biopsy for severe respiratory failure: A systematic review and meta-analysis.Respiratory investigation · 2023Pooled it
- A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality.Critical care (London, England) · 2020Pooled it
- Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.Stem cell research & therapy · 2022Trial
- The relationship between the chronological phases of diffuse alveolar damage and clinical outcomes in acute respiratory distress syndrome.Journal of intensive care · 2026Article
- MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.Stem cell research & therapy · 2026Review
- Chest Computed Tomography Patterns Associated with Severity in Adults with Respiratory Syncytial Virus Infection: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Acute Respiratory Distress Syndrome and Spondylitis Secondary to Salmonella Bacteremia.Cureus · 2025Article
- Compositional changes of the lung extracellular matrix in acute respiratory distress syndrome.American journal of physiology. Cell physiology · 2025Article
- Lung tissue expression of epithelial injury markers is associated with acute lung injury severity but does not discriminate sepsis from ARDS.Respiratory research · 2024Article
- Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin DFrontiers in immunology · 2024Article
- A structured diagnostic algorithm for patients with ARDS.Critical care (London, England) · 2023Review
- Feasibility and Safety of Transbronchial Lung Cryobiopsy for Diagnosis of Acute Respiratory Failure with Mechanical Ventilation in Intensive Care Unit.Diagnostics (Basel, Switzerland) · 2022Article
- Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms.Regenerative therapy · 2022Review
- Effects of High-Resolution CT Changes on Prognosis Predictability in Acute Respiratory Distress Syndrome with Diffuse Alveolar Damage.Journal of clinical medicine · 2022Article
- Influence of photobiomodulation therapy on the treatment of pulmonary inflammatory conditions and its impact on COVID-19.Lasers in medical science · 2022Article
- Relationship between Mechanical Ventilation and Histological Fibrosis in Patients with Acute Respiratory Distress Syndrome Undergoing Open Lung Biopsy.Journal of personalized medicine · 2022Article
- Acute exacerbation of interstitial lung disease associated with rheumatic disease.Nature reviews. Rheumatology · 2022Review
- Breath octane and acetaldehyde as markers for acute respiratory distress syndrome in invasively ventilated patients suspected to have ventilator-associated pneumonia.ERJ open research · 2022Article
- Breath analysis for detection and trajectory monitoring of acute respiratory distress syndrome in swine.ERJ open research · 2022Article
- Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies.Regenerative therapy · 2021Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiffuse alveolar damage (DAD) is the pathological hallmark of acute respiratory distress syndrome (ARDS), however, the presence of DAD in the clinical criteria of ARDS patients by Berlin definition is little known. This study is designed to investigate the role of DAD in ARDS patients who underwent open lung biopsy.
methodsWe retrospectively reviewed all ARDS patients who met the Berlin definition and underwent open lung biopsy from January 1999 to January 2014 in a referred medical center. DAD is characterized by hyaline membrane formation, lung edema, inflammation, hemorrhage and alveolar epithelial cell injury. Clinical data including baseline characteristics, severity of ARDS, clinical and pathological diagnoses, and survival outcomes were analyzed.
resultsA total of 1838 patients with ARDS were identified and open lung biopsies were performed on 101 patients (5.5 %) during the study period. Of these 101 patients, the severity of ARDS on diagnosis was mild of 16.8 %, moderate of 56.5 % and severe of 26.7 %. The hospital mortality rate was not significant difference between the three groups (64.7 % vs 61.4 % vs 55.6 %, p = 0.81). Of the 101 clinical ARDS patients with open lung biopsies, 56.4 % (57/101) patients had DAD according to biopsy results. The proportion of DAD were 76.5 % (13/17) in mild, 56.1 % (32/57) in moderate and 44.4 % (12/27) in severe ARDS and there is no significant difference between the three groups (p = 0.113). Pathological findings of DAD patients had a higher hospital mortality rate than non-DAD patients (71.9 % vs 45.5 %, p = 0.007). Pathological findings of DAD (odds ratio: 3.554, 95 % CI, 1.385-9.12; p = 0.008) and Sequential Organ Failure Assessment score on the biopsy day (odds ratio: 1.424, 95 % CI, 1.187-1.707; p<0.001) were significantly and independently associated with hospital mortality. The baseline demographics and clinical characteristics were not significantly different between DAD and non-DAD patients.
conclusionsThe correlation of pathological findings of DAD and ARDS diagnosed by Berlin definition is modest. A pathological finding of DAD in ARDS patients is associated with hospital mortality and there are no clinical characteristics that could identify DAD patients before open lung biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.